Streetbeat News

Analyst Ratings

VSTO

Aegis Capital has downgraded Vista Outdoor (NYSE:VSTO) from Buy to Hold, with a new price target of $40, as announced by analyst Rommel Dionisio.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:27 pm

CAKE

JP Morgan analyst John Ivankoe maintains an Underweight rating on Cheesecake Factory (NASDAQ:CAKE) and lowers the price target from $40 to $38.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:27 pm

NVTS

Morgan Stanley analyst Joseph Moore maintains an Equal-Weight rating on Navitas Semiconductor (NASDAQ:NVTS) but lowers the price target from $4.6 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:25 pm

SNDX

JP Morgan analyst Anupam Rama maintains an Overweight rating on Syndax Pharmaceuticals (NASDAQ:SNDX) but lowers the price target from $34 to $33.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:25 pm

DH

Morgan Stanley analyst Craig Hettenbach maintains an Equal-Weight rating on Definitive Healthcare (NASDAQ:DH) but lowers the price target from $9 to $5.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:24 pm

SIBN

Morgan Stanley analyst Drew Ranieri maintains an Overweight rating on SI-BONE (NASDAQ:SIBN) but lowers the price target from $21 to $19.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:23 pm

SAGE

JP Morgan analyst Anupam Rama maintains a Neutral rating on Sage Therapeutics (NASDAQ:SAGE) but lowers the price target from $12 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:23 pm

VRRM

Morgan Stanley analyst James Faucette maintains an Equal-Weight rating on Verra Mobility (NASDAQ:VRRM) and raises the price target from $22 to $27.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:23 pm

MGA

JP Morgan analyst Ryan Brinkman maintains an Overweight rating on Magna International (NYSE:MGA) but lowers the price target from $63 to $55.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:22 pm

HALO

JP Morgan analyst Jessica Fye maintains an Overweight rating on Halozyme Therapeutics (NASDAQ:HALO) but lowers the price target from $53 to $52.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 4:21 pm